Ethnic disparity in Israel impacts long-term results after heart transplantation.
Adult
Arabs
/ statistics & numerical data
Ethnicity
/ statistics & numerical data
Female
Graft Rejection
/ epidemiology
Health Status Disparities
Heart Transplantation
/ methods
Humans
Israel
/ epidemiology
Jews
/ statistics & numerical data
Kaplan-Meier Estimate
Length of Stay
/ trends
Male
Middle Aged
Postoperative Complications
/ epidemiology
Risk Factors
Arabs
Cardiac allograft vasculopathy
Cardiovascular mortality
Ethnicity
Heart transplantation
Jews
Journal
Israel journal of health policy research
ISSN: 2045-4015
Titre abrégé: Isr J Health Policy Res
Pays: England
ID NLM: 101584158
Informations de publication
Date de publication:
14 Jan 2019
14 Jan 2019
Historique:
received:
07
06
2018
accepted:
10
12
2018
entrez:
15
1
2019
pubmed:
15
1
2019
medline:
17
9
2019
Statut:
epublish
Résumé
Ethnicity may affect graft longevity and recipient mortality after heart transplantation (HTx). We hypothesized that differences in ethnic origin between Arabs and Jews undergoing HTx in Israel may contribute to differences in long-term outcomes. The study population comprised all 254 patients who underwent HTx between 1991 and 2017 in a tertiary medical center located in the center of Israel. Patients were categorized as either Jews (226 patients, 89%) or Arabs (28 patients, 11%). The primary end point was cardiac allograft vasculopathy (CAV), secondary end points were cardiovascular (CV) mortality and the combined end point of CAV/CV mortality. In comparison with Jews, Arab patients were significantly younger (ave. age 42 vs. 50) and had shorter in-hospital stay (45 vs. 80 days). However, Kaplan-Meier survival analysis showed that at 10 years of follow-up CAV rates were significantly higher among Arabs (58%) compared with Jews (23%; log-rank P = 0.01) for the overall difference during follow-up. Similar results were shown for the separate end point of CV mortality and the combined end point of CAV/CV mortality. Multivariate analysis, which controlled for age, gender, statin treatment, and other potential confounders, showed that Arab recipient ethnic origin was associated with a significant > 2.5-fold (p = 0.01) increase in the risk for CAV; a > 4-fold increase in the risk for CV mortality (p = 0.001); and approximately 4-fold increase in the risk for the combined end point (p = 0.001). These findings were validated by propensity score analysis. Our data suggest that Arab ethnic origin is associated with a significantly increased risk for CAV and mortality following HTx. Suggested explanations contributing to ethnic disparities in Israel include socioeconomic, environmental and genetic factors. Further studies are required to evaluate whether more aggressive risk factor management in the Israeli Arab population following HTx would reduce CAV and CV mortality in this high-risk population. Increased awareness and early intervention of the Israeli healthcare system and cooperation with the Arab community is of paramount importance.
Sections du résumé
BACKGROUND
BACKGROUND
Ethnicity may affect graft longevity and recipient mortality after heart transplantation (HTx). We hypothesized that differences in ethnic origin between Arabs and Jews undergoing HTx in Israel may contribute to differences in long-term outcomes.
METHODS
METHODS
The study population comprised all 254 patients who underwent HTx between 1991 and 2017 in a tertiary medical center located in the center of Israel. Patients were categorized as either Jews (226 patients, 89%) or Arabs (28 patients, 11%). The primary end point was cardiac allograft vasculopathy (CAV), secondary end points were cardiovascular (CV) mortality and the combined end point of CAV/CV mortality.
RESULTS
RESULTS
In comparison with Jews, Arab patients were significantly younger (ave. age 42 vs. 50) and had shorter in-hospital stay (45 vs. 80 days). However, Kaplan-Meier survival analysis showed that at 10 years of follow-up CAV rates were significantly higher among Arabs (58%) compared with Jews (23%; log-rank P = 0.01) for the overall difference during follow-up. Similar results were shown for the separate end point of CV mortality and the combined end point of CAV/CV mortality. Multivariate analysis, which controlled for age, gender, statin treatment, and other potential confounders, showed that Arab recipient ethnic origin was associated with a significant > 2.5-fold (p = 0.01) increase in the risk for CAV; a > 4-fold increase in the risk for CV mortality (p = 0.001); and approximately 4-fold increase in the risk for the combined end point (p = 0.001). These findings were validated by propensity score analysis.
CONCLUSIONS
CONCLUSIONS
Our data suggest that Arab ethnic origin is associated with a significantly increased risk for CAV and mortality following HTx. Suggested explanations contributing to ethnic disparities in Israel include socioeconomic, environmental and genetic factors. Further studies are required to evaluate whether more aggressive risk factor management in the Israeli Arab population following HTx would reduce CAV and CV mortality in this high-risk population. Increased awareness and early intervention of the Israeli healthcare system and cooperation with the Arab community is of paramount importance.
Identifiants
pubmed: 30636628
doi: 10.1186/s13584-018-0271-7
pii: 10.1186/s13584-018-0271-7
pmc: PMC6330742
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3Commentaires et corrections
Type : CommentIn
Références
J Pediatr Genet. 2015 Mar;4(1):1-8
pubmed: 27617109
Eur J Public Health. 2016 Jun;26(3):433-8
pubmed: 26612884
J Heart Lung Transplant. 2009 Apr;28(4):320-7
pubmed: 19332257
J Nutr. 2012 Dec;142(12):2175-81
pubmed: 23096004
J Am Soc Nephrol. 2005 Jan;16(1):269-77
pubmed: 15563568
J Biomed Biotechnol. 2001;1(3):129-132
pubmed: 12488606
J Heart Lung Transplant. 1998 Aug;17(8):744-53
pubmed: 9730422
N Engl J Med. 1995 Sep 7;333(10):621-7
pubmed: 7637722
JAMA. 1993 Nov 17;270(19):2307-15
pubmed: 8230592
Circ Heart Fail. 2011 Mar;4(2):153-60
pubmed: 21228316
Am J Transplant. 2016 Nov;16(11):3299-3300
pubmed: 27737501
J Heart Lung Transplant. 2005 Nov;24(11):1710-20
pubmed: 16297770
Women Health. 2008;48(2):145-66
pubmed: 19042214
Ann Thorac Surg. 2010 Jun;89(6):1956-63; discussion 1963-4
pubmed: 20494056
Am J Transplant. 2006 Nov;6(11):2556-62
pubmed: 16952299
J Heart Lung Transplant. 2010 Jul;29(7):717-27
pubmed: 20620917
Clin Transplant. 2017 Dec;31(12):
pubmed: 28990263
Circulation. 2011 Apr 19;123(15):1642-9
pubmed: 21464049
Clin Transplant. 2017 Nov;31(11):
pubmed: 28886227
Am J Cardiol. 2010 Apr 1;105(7):1024-9
pubmed: 20346325
PLoS One. 2017 May 8;12(5):e0176661
pubmed: 28481942
Am J Cardiol. 2015 Apr 15;115(8):1102-6
pubmed: 25743210
J Heart Lung Transplant. 2017 Oct;36(10):1037-1046
pubmed: 28779893
Transplant Proc. 2007 Dec;39(10):3297-302
pubmed: 18089375
S Afr Med J. 1967 Dec 30;41(48):1271-4
pubmed: 4170370
J Heart Lung Transplant. 2016 Aug;35(8):953-61
pubmed: 27080415
Circulation. 2003 Jan 7;107(1):93-7
pubmed: 12515749
J Am Coll Cardiol. 2013 Dec 17;62(24):2308-15
pubmed: 23994416
Pediatr Transplant. 2013 Aug;17(5):436-40
pubmed: 23714284
Am J Hum Genet. 1994 Jul;55(1):34-41
pubmed: 8023850